These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 2523865

  • 1. Soluble forms of CD21 and CD23 antigens in the serum in B cell chronic lymphocytic leukaemia.
    Lowe J, Brown B, Hardie D, Richardson P, Ling N.
    Immunol Lett; 1989 Jan 31; 20(2):103-9. PubMed ID: 2523865
    [Abstract] [Full Text] [Related]

  • 2. CD23 antigen expression in CLL.
    Gibson J, Neville S, Joshua D, Kronenberg H.
    Br J Haematol; 1989 Aug 31; 72(4):598. PubMed ID: 2528370
    [No Abstract] [Full Text] [Related]

  • 3. Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL).
    Ling NR, Stevenson FK, Brown B.
    Clin Exp Immunol; 1991 Dec 31; 86(3):360-6. PubMed ID: 1721010
    [Abstract] [Full Text] [Related]

  • 4. CD23 antigen regulation and signaling in chronic lymphocytic leukemia.
    Fournier S, Delespesse G, Rubio M, Biron G, Sarfati M.
    J Clin Invest; 1992 Apr 31; 89(4):1312-21. PubMed ID: 1532590
    [Abstract] [Full Text] [Related]

  • 5. Expression of CD23 antigen and its regulation by IL-4 in chronic lymphocytic leukemia.
    Sarfati M, Fournier S, Christoffersen M, Biron G.
    Leuk Res; 1990 Apr 31; 14(1):47-55. PubMed ID: 2137545
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2.
    Billaud M, Busson P, Huang D, Mueller-Lantzch N, Rousselet G, Pavlish O, Wakasugi H, Seigneurin JM, Tursz T, Lenoir GM.
    J Virol; 1989 Oct 31; 63(10):4121-8. PubMed ID: 2550660
    [Abstract] [Full Text] [Related]

  • 7. Phenotypic analysis of receptor-ligand pairs on B-cells in B-chronic lymphocytic leukemia.
    Gagro A, Dasić G, Sabioncello A, Rabatić S, Reckzeh B, Havemann K, Kardum I, Jacksić B, Vitale B.
    Leuk Lymphoma; 1997 Apr 31; 25(3-4):301-11. PubMed ID: 9168440
    [Abstract] [Full Text] [Related]

  • 8. Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia.
    Lopez-Matas M, Rodriguez-Justo M, Morilla R, Catovsky D, Matutes E.
    Haematologica; 2000 Nov 31; 85(11):1140-5. PubMed ID: 11064465
    [Abstract] [Full Text] [Related]

  • 9. CD21 is a ligand for CD23 and regulates IgE production.
    Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY.
    Nature; 1992 Aug 06; 358(6386):505-7. PubMed ID: 1386409
    [Abstract] [Full Text] [Related]

  • 10. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia.
    Geisler CH, Larsen JK, Hansen NE, Hansen MM, Christensen BE, Lund B, Nielsen H, Plesner T, Thorling K, Andersen E.
    Blood; 1991 Oct 01; 78(7):1795-802. PubMed ID: 1717071
    [Abstract] [Full Text] [Related]

  • 11. Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.
    Tooze JA, Bevan DH.
    Clin Exp Immunol; 1991 Mar 01; 83(3):423-9. PubMed ID: 1825940
    [Abstract] [Full Text] [Related]

  • 12. The Fc epsilon R2/CD23 antigen: a hallmark of chronic lymphocytic leukemia B cells.
    Almerigogna F, Biagiotti R, Giudizi MG, Alessi A, Ricci M, Bosi A, Romagnani S.
    Ric Clin Lab; 1989 Mar 01; 19(2):129-38. PubMed ID: 2528201
    [Abstract] [Full Text] [Related]

  • 13. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells.
    Shubinsky G, Schlesinger M, Polliack A, Rabinowitz R.
    Leuk Lymphoma; 1997 May 01; 25(5-6):521-30. PubMed ID: 9250823
    [Abstract] [Full Text] [Related]

  • 14. CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cell lines to specific CD4+ T cell clones.
    Grosjean I, Lachaux A, Bella C, Aubry JP, Bonnefoy JY, Kaiserlian D.
    Eur J Immunol; 1994 Dec 01; 24(12):2982-6. PubMed ID: 7805725
    [Abstract] [Full Text] [Related]

  • 15. Activation and immortalization of leukaemic B cells by Epstein-Barr virus.
    Walls EV, Doyle MG, Patel KK, Allday MJ, Catovsky D, Crawford DH.
    Int J Cancer; 1989 Nov 15; 44(5):846-53. PubMed ID: 2555307
    [Abstract] [Full Text] [Related]

  • 16. The in vivo expression of type B CD23 mRNA in B-chronic lymphocytic leukemic cells is associated with an abnormally low CD23 upregulation by IL-4: comparison with their normal cellular counterparts.
    Fournier S, Tran ID, Suter U, Biron G, Delespesse G, Sarfati M.
    Leuk Res; 1991 Nov 15; 15(7):609-18. PubMed ID: 1830631
    [Abstract] [Full Text] [Related]

  • 17. Phenotypic analysis of B-cells extracted from human periodontal disease tissue.
    Gemmell E, Seymour GJ.
    Oral Microbiol Immunol; 1991 Dec 15; 6(6):356-62. PubMed ID: 1668249
    [Abstract] [Full Text] [Related]

  • 18. Synergy test for recognition of epitopes on soluble proteins; its application in the study of CD21 and CD23 antigens and their respective antibodies.
    Ling NR, Brown B, Hardie D.
    J Immunol Methods; 1994 Jul 12; 173(1):11-7. PubMed ID: 7518487
    [Abstract] [Full Text] [Related]

  • 19. Phenotypic heterogeneity of B cell chronic lymphocytic leukaemia.
    Merson A, Brochier J.
    Immunol Lett; 1988 Dec 12; 19(4):269-71. PubMed ID: 3266609
    [Abstract] [Full Text] [Related]

  • 20. Heterogeneity of CLL: high CD23 antigen and alpha IFN receptor expression are features of favourable disease and of cell activation.
    Dadmarz R, Cawley JC.
    Br J Haematol; 1988 Mar 12; 68(3):279-82. PubMed ID: 2965599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.